Optical Diffraction Tomography and Raman Confocal Microscopy for the Investigation of Vacuoles Associated with Cancer Senescent Engulfing Cells.
Raman spectroscopy
cancer
cell engulfing
cell in cell
microscopy
optical diffraction tomography
therapy-induced senescence
vacuole
Journal
Biosensors
ISSN: 2079-6374
Titre abrégé: Biosensors (Basel)
Pays: Switzerland
ID NLM: 101609191
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
30
09
2023
revised:
20
10
2023
accepted:
04
11
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Wild-type p53 cancer therapy-induced senescent cells frequently engulf and degrade neighboring ones inside a massive vacuole in their cytoplasm. After clearance of the internalized cell, the vacuole persists, seemingly empty, for several hours. Despite large vacuoles being associated with cell death, this process is known to confer a survival advantage to cancer engulfing cells, leading to therapy resistance and tumor relapse. Previous attempts to resolve the vacuolar structure and visualize their content using dyes were unsatisfying for lack of known targets and ineffective dye penetration and/or retention. Here, we overcame this problem by applying optical diffraction tomography and Raman spectroscopy to MCF7 doxorubicin-induced engulfing cells. We demonstrated a real ability of cell tomography and Raman to phenotype complex microstructures, such as cell-in-cells and vacuoles, and detect chemical species in extremely low concentrations within live cells in a completely label-free fashion. We show that vacuoles had a density indistinguishable to the medium, but were not empty, instead contained diluted cell-derived macromolecules, and we could discern vacuoles from medium and cells using their Raman fingerprint. Our approach is useful for the noninvasive investigation of senescent engulfing (and other peculiar) cells in unperturbed conditions, crucial for a better understanding of complex biological processes.
Identifiants
pubmed: 37998148
pii: bios13110973
doi: 10.3390/bios13110973
pmc: PMC10669708
pii:
doi:
Substances chimiques
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB015871
Pays : United States
Organisme : NCI NIH HHS
ID : UG3 CA275687
Pays : United States
Organisme : NIH HHS
ID : UG3CA275687
Pays : United States
Organisme : NIH HHS
ID : P41EB015871
Pays : United States
Références
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
J Biomed Opt. 2018 Jun;23(7):1-23
pubmed: 29956506
Nat Rev Clin Oncol. 2022 Oct;19(10):619-636
pubmed: 36045302
J Natl Cancer Inst. 2017 Jul 1;109(7):
pubmed: 28376176
Nat Commun. 2020 Sep 24;11(1):4830
pubmed: 32973134
Nature. 2013 Mar 21;495(7441):375-8
pubmed: 23485973
Exp Cell Res. 2017 Sep 15;358(2):253-259
pubmed: 28673821
J Clin Invest. 2018 Apr 2;128(4):1238-1246
pubmed: 29608137
Adv Protein Chem Struct Biol. 2023;133:115-158
pubmed: 36707199
Biomed Opt Express. 2011 Sep 1;2(9):2484-92
pubmed: 21991542
Light Sci Appl. 2020 Jan 28;9:11
pubmed: 32025294
Sensors (Basel). 2016 Dec 14;16(12):
pubmed: 27983660
Biomed Pharmacother. 2017 Nov;95:1209-1218
pubmed: 28931213
Mol Biol Cell. 2013 Dec;24(23):3736-45
pubmed: 24088573
J Biomed Opt. 2008 Jul-Aug;13(4):044027
pubmed: 19021354
Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):28-32
pubmed: 22184220
Front Mol Biosci. 2021 Dec 15;8:779702
pubmed: 34977157
Sci Adv. 2023 Sep 15;9(37):eadg6231
pubmed: 37703362
Int J Cancer. 2016 Jan 15;138(2):489-96
pubmed: 26238069
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16687-92
pubmed: 24065823
Materials (Basel). 2021 Jul 03;14(13):
pubmed: 34279303
Soft Matter. 2021 Jan 28;17(4):853-862
pubmed: 33232425
Adv Funct Mater. 2021 Oct 20;31(43):
pubmed: 34924914
J Cell Biol. 2019 Nov 4;218(11):3827-3844
pubmed: 31530580
Oncotarget. 2016 Aug 23;7(34):55863-55889
pubmed: 27331412
Lab Invest. 2021 Sep;101(9):1267-1280
pubmed: 34117364
Cell Death Dis. 2021 Jan 22;12(1):119
pubmed: 33483474
Adv Drug Deliv Rev. 2015 Jul 15;89:71-90
pubmed: 25728764
Nat Rev Cancer. 2018 Dec;18(12):758-766
pubmed: 30420767
Mol Cell Oncol. 2019 Dec 10;7(1):1688601
pubmed: 31993500
Cancer Manag Res. 2020 Dec 31;12:13553-13566
pubmed: 33408525
Anat Rec (Hoboken). 2012 Dec;295(12):2031-6
pubmed: 23060362
Biomed J. 2017 Jun;40(3):133-140
pubmed: 28651734
Sci Rep. 2021 Jan 18;11(1):1698
pubmed: 33462309
Nat Methods. 2007 Sep;4(9):717-9
pubmed: 17694065
Bioarchitecture. 2013 Jan-Feb;3(1):13-9
pubmed: 23572040
Front Neuroanat. 2019 Aug 20;13:81
pubmed: 31481881
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13730-5
pubmed: 18772382
Front Oncol. 2020 Jun 30;10:908
pubmed: 32695662
Breast Cancer Res. 2018 Oct 1;20(1):115
pubmed: 30285883
Nutrients. 2022 Sep 02;14(17):
pubmed: 36079891
Sensors (Basel). 2013 Mar 28;13(4):4170-91
pubmed: 23539026
Sci Rep. 2017 Sep 7;7(1):10829
pubmed: 28883655
Nano Lett. 2015 Mar 11;15(3):1766-72
pubmed: 25646716
Analyst. 2008 Oct;133(10):1416-23
pubmed: 18810290
Cancers (Basel). 2020 Jan 09;12(1):
pubmed: 31936526
Biomolecules. 2020 Mar 08;10(3):
pubmed: 32182711
Cells. 2022 Dec 24;12(1):
pubmed: 36611874